- Home
- Responsibility
- CR Review 2007
- Case studies
- Opening a new research centre in China
Case study
Opening a new research centre in China
As well as focusing on patient safety, our R&D is expanding in new areas. We are opening a new R&D facility in China which will focus on R&D into neurodegenerative disorders such as Parkinson's disease, multiple sclerosis and Alzheimer's.
The new centre will enable us to increase focus and depth in important disease areas and to benefit from accessing the vast talent pool and knowledge in life sciences in China, while continuing to strengthen our global R&D capabilities. The costs of conducting research in China are relatively lower than those in other markets. However, lower costs are not the reason behind the decision to set up this new facility.
Our R&D in China will be conducted to GSK's global quality and ethical standards all our R&D policies and monitoring procedures will apply to our operations in China. Significant above country resource, as well as local resource in China is being committed to ensure that the establishment of our facilities and their subsequent operation complies with both Chinese requirements and GSK's global standards.
